Study of Suramin in Subjects With Furosemide-Resistant AKI

Overview

This is a prospective, double-blind, randomized, placebo-controlled study to assess the effects of suramin as a potential treatment option to prevent subjects with AKI from progressing to Kidney Disease Improving Global Outcomes (KDIGO) Stage III or dialysis dependent AKI.

Full Title of Study: “A Prospective, Double-Blind, Placebo-controlled Study of Suramin in Subjects With Furosemide-Resistant Acute Kidney Injury (AKI): Efficacy in Preventing Dialysis Dependent AKI”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: April 17, 2023

Interventions

  • Drug: Suramin
    • Suramin is administered via IV infusion as a single dose of 3 mg/kg
  • Drug: Placebo
    • Placebo

Arms, Groups and Cohorts

  • Experimental: Suramin
  • Placebo Comparator: Placebo

Clinical Trial Outcome Measures

Primary Measures

  • To evaluate and compare the efficacy of a single 3.0 mg/kg infusion of suramin versus placebo in subjects with diuretic unresponsive AKI
    • Time Frame: 7 days
    • The difference between the effect of a 3.0 mg/kg infusion of suramin versus placebo will be based on meeting 2 or more of the composite event endpoints of: peak serum creatinine (Cr) of 6 mg/dL or above from investigational product (IP) infusion through Day or progression to KDIGO Stage III within 72 hours (hr) from IP infusion or death or dialysis from IP infusion through Day 7.

Participating in This Clinical Trial

Inclusion Criteria

  • At least 18 years of age at the time of signing the informed consent – KDIGO Stage I AKI and a serum Cr increase ≥ 0.3 mg/dL within 48 hr or 1.5 to 1.9-times baseline (pre-FST) Cr levels within 48 hr (± 6 hr) prior to randomization OR KDIGO Stage II AKI and serum Cr increase 2.0 to 2.9-times baseline (pre-FST) Cr levels within 48 hr (± 6 hr) prior to randomization – Fails to achieve a 200 mL increase in urine output within 2 hr following a 1.0 mg/kg bolus of furosemide (i.e., positive FST) – If female of childbearing potential, must have a negative pregnancy test at Screening Is capable of providing informed consent as described in in this protocol. Exclusion Criteria:

  • Receiving hemodialysis or peritoneal dialysis – Prior renal transplant (other organ transplants are not excluded) – Known baseline (pre-FST) estimated glomerular filtration rate (eGFR) ≤ 20 mL/min – Evidence of hydronephrosis or obstructive uropathy confirmed by renal ultrasound (for subjects without a documented ultrasound, the – Investigator will determine if a renal ultrasound is indicated, consistent with the standard of care (SOC) – Hepatic encephalopathy, Child class C cirrhosis, and/or clinical suspicion of hepatorenal syndrome – International normalized ratio (INR) ≤ 3.0, unless on stable long-term warfarin therapy within 2 weeks prior to randomization – Known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection – Known coronavirus (COVID-19) infection – White blood cell count (WBC) < 2,000/μL and/or platelet count < 30,000/μL at the time of Screening – A sequential organ failure assessment (SOFA) score > 10 during Screening – Subjects requiring 3 or more vasopressor agents of any combination to maintain a mean arterial pressure > 65 mm Hg – Unwilling to participate in follow-up phone surveys up to 180 days post-treatment – Are enrolled in another interventional research study or have participated in another interventional study within 14 days of Screening.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rediscovery Life Sciences
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.